List view

• Broader profiling and interpretation of the tumor's mutations

  Combines the following TODO list for the neoantigen pipeline: 1) Driver mutations in the VCFs 2) MHC expression via seq2hla 3) Loss of antigen presentation via mutations in TAP, B2M, and if we can get any of the MHC mutation programs running — deleterious MHC variants. 4) Run fusion catcher or any other RNA-seq fusion program on samples A/B/C

  Overdue by 7 year(s)

  •

  Due by July 16, 2018

  •1/9 issues closed
  11% complete8 open1 closed